[Efficacy and tolerability of cefazedone in infectious skin diseases; determination of serum and tissue concentrations (author's transl)].
The efficacy and tolerance of Cefazedone, a new Cephalosporin derivate, were investigated in an open clinical trial on 40 patients with bacteriological skin infections. Patients with Erysipelas, impetiginized dermatoses and Pyodermia were treated during an average period of 9 days mainly with a dosage of 2X1 g i.v., in some cases with 2X2 g i.v. daily. The success of the treatment was good--very good in 92% of the cases. All pathogens isolated before treatment (Streptococci, St. aureus, E. coli) were eliminated after treatment. 2 patients showed transitory incompatibility reactions due to too rapid injections. The local and systemic tolerance were excellent in all other cases. 1 hour after i.v. injection of 1 g Cefazedone to 20 patients the mean concentration in the serum was 51 micrograms per ml and in the skin-tissue 10.6 micrograms/g.
D000328:Adult; D000368:Aged; D002511:Cephalosporins / Q000008:administration & dosage / Q000009:adverse effects*; D004361:Drug Tolerance; D005069:Evaluation Studies as Topic; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D012874:Skin Diseases, Infectious / Q000188:drug therapy*
D002511:Cephalosporins
Wirksamkeit und Verträglichkeit von Cefazedon bei bakteriellen Infektionskrankheiten der Haut; Bestimmung von Serum- und Gewebekonzentrationen.